Abbott Laboratories sets Q2 earnings date, shares trade firmly on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:00.

Abbott Laboratories (US0028241000) has scheduled its second-quarter 2026 earnings release for mid-July, according to its investor relations calendar on the company’s NYSE listing. The healthcare group remains a constituent of the S&P 500, making the update relevant for broad U.S. equity benchmarks.

What Abbott has scheduled next

Abbott plans to report its Q2 2026 results and hold a corresponding conference call in the week of July 15, as indicated in its official earnings calendar on the investor relations site, with management expected to comment on diagnostics and medical devices performance. The company traditionally publishes results before the U.S. market open on the NYSE and follows with a webcast for analysts and investors the same day.

The July release will follow Abbott’s first-quarter 2026 update, where the group reported mid-single-digit organic sales growth and reiterated its full-year earnings guidance, according to prior company disclosures and coverage by major financial media. The upcoming figures will provide a new data point on key lines such as cardiovascular devices and glucose monitoring systems, which are central to investor models.

How analysts rate the shares

Consensus data compiled by sell-side aggregators show that most analysts maintain Buy or Overweight ratings on Abbott, with an average 12-month price target in the low 110-dollar range, implying double-digit upside from current levels. According to a recent MarketBeat overview, large houses such as Morgan Stanley and JPMorgan keep positive stances on the stock, citing Abbott’s diversified healthcare portfolio and stable cash generation.

Some research notes in June highlighted a balanced risk-reward profile, with upside tied to procedure volumes and new product launches, while foreign-exchange and pricing remain watch points. In aggregate, the consensus backdrop appears constructive ahead of the July earnings event, even though target dispersion reflects different views on long-term growth in diagnostics and nutrition.

The products behind the earnings

Abbott generates revenue across medical devices, diagnostics, established pharmaceuticals and nutrition, with flagship products including its FreeStyle Libre continuous glucose monitoring system and Alinity diagnostics platforms. FreeStyle Libre, in particular, has seen strong adoption in diabetes care, supported by clinical data and broader reimbursement in multiple markets.

Where the stock trades today

The Abbott Laboratories shares (US0028241000) trade on the NYSE at 93.12 U.S. dollars as of 2026-06-25, 15:59 Eastern Time.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.